About Nektar Therapeutics
- Industry: Pharmaceuticals
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.nektar.com/
Frequently Asked Questions
What is the 52-week range for NKTR?
The 52-week high is $109 and the 52-week low is $33.4.
What is the P/E ratio for NKTR?
The P/E ratio data is currently unavailable.
What is the dividend yield for NKTR?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -37.54%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -284.39%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 9.57.
Analyst Recommendation Trends
Wall Street analyst consensus for NKTR over the last few months:
Latest NKTR News
Nektar Therapeutics: Downgrade To Hold On REZPEG Market Outlook Setback And More
Nektar Therapeutics downgraded to Hold: REZPEG shows strong efficacy but safety risks. Learn what this means for AA/AD trials and NKTR investors.
HC Wainwright & Co. Reiterates Buy on Nektar Therapeutics, Maintains $185 Price Target
HC Wainwright & Co. analyst Arthur He reiterates Nektar Therapeutics (NASDAQ:NKTR) with a Buy and maintains $185 price target.
Nektar Posted Promising Alopecia Results. Here's Why It Took A 22% Beating.
Nektar Therapeutics stock took a hit Thursday despite test results that suggested its drug has long-term benefits for alopecia patients.
NKTR Stock Eyes Worst Day In Over 3 Years On Rezpeg Data: William Blair Still Sees A Durability Edge
Nektar on Thursday announced data from two trials of its drug rezpegaldesleukin in alopecia and eczema.
This Biotech Had Good News for Hair Loss Sufferers. So Why Is the Stock Sinking?
Nektar Therapeutics reports sustained hair regrowth after treatment ended, while analysts see positive implications for a competing drug.
Nektar REZPEG Data Show Durable Hair Regrowth, Set Up Phase III Alopecia Trial
Nektar Therapeutics (NASDAQ:NKTR) presented new clinical and biomarker findings for rezpegaldesleukin, or REZPEG, at the EADV 2026 Congress, highlighting six-month off-treatment results in severe to very severe alopecia areata and molecular findings from its Phase IIb atopic dermatitis program. REZ
3 Biotech Stocks Put Traders Are Targeting Today
NKTR, QSI, and PACB are drawing attention from options bears
/UPDATE -- Nektar Therapeutics/
Nektar Therapeutics (Nasdaq: NKTR) today announced that long-term data on rezpegaldesleukin from the Phase 2b REZOLVE-AA and Phase 2b REZOLVE-AD studies are being presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026 in Vienna, Austria in two oral presentation sessions.
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Nexalin Technology (NASDAQ:NXL) shares increased by 77.8% to $7.61 during Thursday's regular session. The company's market cap stands at $3.5 million. Stablecoin Development (AMEX:SDEV) stock rose
Nektar Therapeutics (NKTR) Shareholder/Analyst Call Transcript
Nektar Therapeutics (NKTR) Shareholder/Analyst Call October 1, 2026 8:00 AM EDTCompany ParticipantsVivian WuMary Tagliaferri - Chief Medical OfficerJonathan...
Nektar Therapeutics Presents Data On Rezpegaldesleukin From Its Phase 2b REZOLVE-A, Phase 2b REZOLVE-AD Trials At European Academy Of Dermatology And Venereology
Nektar Therapeutics (Nasdaq: NKTR) today announced that long-term data on rezpegaldesleukin from the Phase 2b REZOLVE-AA and Phase 2b REZOLVE-AD studies are being presented at the European Academy of Dermatology and
New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients with Atopic Dermatitis
Nektar Therapeutics (Nasdaq: NKTR) and collaborators at the Icahn School of Medicine at Mount Sinai today announced new results from a multi-omic biomarker sub-study from REZOLVE-AD providing further evidence that rezpegaldesleukin engages its regulatory Tcell (Treg)-mediated mechanism in patients with moderate-to-severe atopic dermatitis, with significant biomarker changes associated with clinical improvement observed as early as Week 2.
How New Rezpegaldesleukin Durability and Mechanistic Data Could Impact Nektar Therapeutics (NKTR) Investors
Nektar Therapeutics recently announced that data from its Phase 2b rezpegaldesleukin trials in atopic dermatitis and alopecia areata were presented in three oral sessions at the 2026 EADV Congress in Vienna, including new 6‑month off‑treatment results in severe alopecia areata and maintenance data in atopic dermatitis. The inclusion of late‑breaking multi‑omic findings from the REZOLVE‑AD biomarker sub‑study adds an unusual level of mechanistic insight that could influence how investors...
What Could Nektar Therapeutics (NKTR) New Rezpegaldesleukin Data Mean For Its Case?
Nektar Therapeutics (NasdaqCM:NKTR) plans three oral presentations on rezpegaldesleukin at the European Academy of Dermatology & Venereology Congress 2026. The talks will share 6‑month off‑treatment durability data from the Phase 2b REZOLVE-AA trial in severe alopecia areata. Multi‑omic biomarker findings from atopic dermatitis patients on rezpegaldesleukin are also scheduled for presentation at EADV 2026. The new rezpegaldesleukin durability and biomarker readouts come in addition to a...
Nektar Announces Three Oral Presentations for Rezpegaldesleukin at the European Academy of Dermatology & Venereology (EADV) Congress 2026
Nektar Therapeutics (Nasdaq: NKTR) announced today that data from its Phase 2b studies of rezpegaldesleukin in atopic dermatitis and alopecia areata will be presented in three separate oral presentations at the European Academy of Dermatology & Venereology (EADV) Congress 2026, to take place September 30 to October 3, 2026, in Vienna, Austria.
Nektar Therapeutics (NKTR) Dropped, So What Is Driving Attention Now?
Nektar Therapeutics (NKTR) has drawn fresh attention after recent share price swings, with the stock down 4% over the past day and 21% over the past month on available return data. At a share price of US$57.06, Nektar Therapeutics has swung sharply lower in the short term, with the 7 day share price return down 14.63% and the 30 day share price return down 21.32%. However, the year to date share price return remains up 31.41%, hinting that recent weakness follows a stronger run earlier in the...
Eli Lilly Wins FDA Approval for Weekly Insulin. Here’s What Comes Next
Key Stats for LLY StockPast week’s performance: 1. 6%52-week range: $716 to $1,293Valuation model target price: $1,834Implied upside: 54.
BTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target
BTIG analyst Julian Harrison reiterates Nektar Therapeutics (NASDAQ:NKTR) with a Buy and maintains $178 price target.
A Jury Awarded Nektar $90 Million From Eli Lilly. Here’s Why the Stock Barely Moved
Key Stats for Eli Lilly StockCurrent Price: $1,183. 46Target Price (Mid): ~$2,060Street Target: ~$1,325Potential Total Return: ~74%Annualized IRR: ~14% / yearWhat Happened?Eli Lilly and Company (LLY) closed essentially flat at $1,183.
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nektar Therapeutics (NASDAQ: NKTR) today announced that, on September 18, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 58,600 shares of its common stock and 2,450 restricted stock units (RSUs) to eleven newly-hired employees under Nektar's 2025 Inducement Plan.
Sector Update: Healthcare Stocks Higher Late Afternoon
Healthcare stocks rose late Friday afternoon with the NYSE Healthcare Index increasing 0.3% and the
Sector Update: Healthcare Stocks Edge Higher in Afternoon Trading
Healthcare stocks edged higher Friday afternoon, with the NYSE Healthcare Index and the State Street
Top Midday Stories: Akamai's $11.6 Billion Anthropic Deal; Scholastic Q1 Loss Widens; Nektar Awarded $90 Million in Eli Lilly Case
All three major US stock indexes were edging higher in midday trading Friday as Treasury yields rema
Update: Nektar Wins $90 Million Jury Verdict Against Eli Lilly Over Rezpegaldesleukin Deal
(Updates to add Eli Lilly's response in the fifth and sixth paragraphs.) Nektar Therapeutics (NK
Eli Lilly Did Breach Implied Covenant of Good Faith With Nektar Therapeutics, Jury Funds
A federal jury in California has awarded Nektar Therapeutics Inc. (NASDAQ:NKTR) $90 million in damages, finding that Eli Lilly and Co. (NYSE:LLY) breached the implied covenant of good faith and fair dealing. Nektar Therapeutics Wins $90 Million Judgment Against Eli Lilly The lawsuit, filed in August 2023, stemmed from a previous licensing agreement between the two companies for the development and commercialization of the drug rezpegaldesleukin. Jury Finds Breach of Covenant The trial in the U.S
Nektar Therapeutics stock rises on $90M jury verdict vs Lilly
Investing.com -- Nektar Therapeutics (NASDAQ:NKTR) shares rose 3.6% in premarket trading Friday following a jury verdict awarding the company $90 million in damages in a contract dispute with Eli Lilly and Company (NYSE:LLY).
Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data
Novo’s latest alliance involves injectables given every one to three months. Elsewhere, Nektar won a legal spat with Eli Lilly and the FDA issued two approvals.
Sector Update: Healthcare Stocks Edge Higher Premarket Friday
Healthcare stocks were edging higher premarket Friday, with the State Street Health Care Select Sect
Nektar Therapeutics Announces That Jury Found Lilly Did Breach Implied Covenant Of Good Faith And Fair Dealing Under License Agreement; Company Awarded $90M In Damages Plus Interest
On September 24, 2026, the jury returned a verdict finding that Lilly breached the implied covenant of good faith and fair dealing in the License Agreement. The jury awarded the Company $90 million in damages plus
Wedbush Maintains Neutral on Nektar Therapeutics, Lowers Price Target to $50
Wedbush analyst Martin Fan maintains Nektar Therapeutics (NASDAQ:NKTR) with a Neutral and lowers the price target from $80 to $50.
Nektar Therapeutics Enters Quiet Period Beginning September 8 Until Public Announcement Of Data From 24-Week Off Treatment Follow-Up Period Of Phase 2b REZOLVE-AA Study Of Rezpegaldesleukin In Patients With Alopecia Areata
-SEC Filing
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-23 | WHITFIELD ROY A | +4,000 | - | - |
| 2026-09-23 | WHITFIELD ROY A | +2,000 | - | - |
| 2026-09-23 | Brainard Diana | +4,000 | - | - |
| 2026-09-23 | Brainard Diana | +2,000 | - | - |
| 2026-09-23 | Ajer Jeffrey Robert | +4,000 | - | - |
| 2026-09-23 | Ajer Jeffrey Robert | +2,000 | - | - |
| 2026-09-23 | CHESS ROBERT | +4,000 | - | - |
| 2026-09-23 | CHESS ROBERT | +2,000 | - | - |
| 2026-09-23 | GREER R SCOTT | +4,000 | - | - |
| 2026-09-23 | GREER R SCOTT | +2,000 | - | - |
| 2026-08-18 | Zalevsky Jonathan | -186 | $71.98 | $13,388 |
| 2026-08-18 | ROBIN HOWARD W | -418 | $71.98 | $30,088 |
| 2026-07-24 | Zalevsky Jonathan | +16,500 | - | - |
| 2026-07-24 | ROBIN HOWARD W | +57,200 | - | - |
| 2026-06-30 | Zalevsky Jonathan | -5,681 | $70 | $397,670 |
| 2026-06-17 | ROBIN HOWARD W | -4,500 | $61.65 | $277,425 |
| 2026-06-17 | ROBIN HOWARD W | -5,500 | $60.81 | $334,455 |
| 2026-06-16 | ROBIN HOWARD W | -4,697 | $60.71 | $285,155 |
| 2026-06-16 | ROBIN HOWARD W | -5,303 | $59.97 | $318,021 |
| 2026-05-19 | Zalevsky Jonathan | -199 | $65.51 | $13,036 |
| 2026-05-19 | ROBIN HOWARD W | -444 | $65.51 | $29,086 |
| 2026-02-18 | Zalevsky Jonathan | -180 | $73 | $13,140 |
| 2026-02-18 | ROBIN HOWARD W | -423 | $73 | $30,879 |
| 2026-01-20 | Zalevsky Jonathan | -3,867 | $35.67 | $137,936 |
| 2025-12-22 | Zalevsky Jonathan | +25,000 | - | - |
| 2025-12-22 | Zalevsky Jonathan | +6,250 | - | - |
| 2025-12-22 | ROBIN HOWARD W | +86,667 | - | - |
| 2025-12-22 | ROBIN HOWARD W | +21,667 | - | - |
| 2025-11-25 | Wilson Mark Andrew | -630 | $54.28 | $34,196 |
| 2025-11-25 | Zalevsky Jonathan | -1,157 | $54.28 | $62,802 |
| 2025-11-25 | ROBIN HOWARD W | -2,207 | $54.28 | $119,796 |
| 2025-11-21 | Wilson Mark Andrew | +3,400 | - | - |
| 2025-11-21 | Wilson Mark Andrew | +1,903 | - | - |
| 2025-11-21 | Zalevsky Jonathan | +4,766 | - | - |
| 2025-11-21 | Zalevsky Jonathan | +2,666 | - | - |
| 2025-11-21 | ROBIN HOWARD W | +12,170 | - | - |
| 2025-11-21 | ROBIN HOWARD W | +7,110 | - | - |